Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has issued a correction disclosure regarding its new facility investment in Plant 5 at Songdo 2nd Bio Campus, updating the total investment amount from KRW 1.9801T to KRW 2.0098T.
📊 [Key Disclosure Details & Financial Figures]
- Disclosure Title: (Correction) New Facility Investment
- Original Filing Date: March 17, 2023
- Reason for Correction: Change in investment amount
- Key Correction Items:
- Investment Amount: (Before) KRW 1,980,100,000,000 ➔ (After) KRW 2,009,800,000,000
- Facility Investment Details (As Revised in Filing):
- Investment Classification: Construction of separate manufacturing plant
- Investment Target: Construction of Plant 5 at Songdo 2nd Bio Campus (Capacity: 180,000L)
- Investment Amount: KRW 2,009,800,000,000
- Equity: KRW 8,995,284,255,250
- Investment Amount to Equity Ratio: 22.34%
- Investment Purpose: Strengthening competitiveness by expanding biopharmaceutical manufacturing capacity
- Investment Period: March 17, 2023 – April 1, 2025
- Board Resolution Date: March 17, 2023 (4 independent directors present)
- Other Important Details:
- The end date of the investment period (April 1, 2025) is subject to change depending on execution dynamics and internal schedules.
- Related Disclosures:
- March 17, 2023: New Facility Investment
- June 05, 2023: New Facility Investment
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Monitoring Plant 5 Investment Adjustment and Project Execution
This correction disclosure provides notice that the facility investment amount for the 180,000L-capacity Plant 5 at Songdo 2nd Bio Campus has been revised upward to KRW 2.0098T.
Tracking the project execution progress and completion timeline through the scheduled end date (April 1, 2025) is essential.
Relevant developments can be verified in subsequent official disclosures and periodic filings.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This content is provided solely for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
